Editor-in-chief
Silvya Stuchi Maria-Engler, Ph.D. Full Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil

Co-Editors
Camila Manoel Crnkovic, Pharm.D., Assistant Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil
Gabriel Lima Barros de Araujo, Pharm.D., Assistant Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil
Inar Castro Erger, Agronomic Engineer, Full Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil
Patricia Melo Aguiar, Pharm.D., Assistant Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil
Silvia Berlanga de Moraes Barros, Pharm.D., Full Professor of School of Pharmaceutical Sciences, University of São Paulo, Brazil

Associated Editors
Arnobio Antonio da Silva Junior, Health Sciences Center, Pharmacy Department, Federal University of Rio Grande do Norte, Brazil
Bingcan Chen, Department of Plant Sciences, North Dakota State University, USA
Carmen Silvia Fávaro-Trindade, Faculty of Animal Science and Food Engineering Department of Food Engineering Pirassununga, University of São Paulo, Brazil
Daniel Pecoraro Demarque, Faculty of Pharmaceutical Sciences, Pharmacy Department, University of São Paulo, Brazil
Guilherme Martins Gelfuso, Faculty of Pharmaceutical Sciences, Pharmacy Department University of Brasília, Brazil
Guilherme Diniz Tavares, Faculty of Pharmacy, Federal University of Juiz de Fora, Brazil
Isabel Vitória Figueiredo, Center of Pharmaceutical Studies, Coimbra Institute for Biomedical Imaging and Translational Research, Portugal
Luciana Oliveira-Cruz, Instituto de Ciencias Naturales, Facultad de Agronomía y Medicina Veterinaria, Campus Santiago Centro, Universidad de las Americas, Chile
Marcia Edilaine Lopes Consolaro, Department of Clinical Analysis and Biomedicine, Health Sciences Center, State University of Maringá, Brazil
Marcílio Cunha Filho, Faculty of Health Sciences, Pharmacy Department, University of Brasília, Brazil
Marcos Luciano Bruschi, Faculty of Pharmaceutical Sciences, Pharmacy Department, State University of Maringá, Brazil
Marlus Chorilli, Faculty of Pharmaceutical Sciences of Araraquara, Department of Pharmaceuticals and Medicines, São Paulo State University, Brazil
Michelle Discacciati de Carvalho, Department of Obstetrics and Gynecology, School of Medical Sciences, Women's Hospital Prof. Dr. José Aristodemo Pinotti/CAISM, State University of Campinas, UNICAMP, Campinas, São Paulo, Brazil
Moacyr Rego, Biochemistry Department, School of Pharmaceutical Science, Federal University of Pernambuco, Brazil
Patrícia Maria Berardo Gonçalves Maia Campos, Faculty of Pharmaceutical Sciences, Ribeirão Preto, University of São Paulo, Brazil
Priscila Schirreff, Freie Universität Berlin, Institute of Pharmacology and Toxicology
Raimar Loebenberg, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Canada.
Rose Mary Zumstein Georg etto Naal, Faculty of Pharmaceutical Sciences, Ribeirão Preto, University of São Paulo, Brazil
Ruy Carlos Beck, Faculty of Pharmaceutical Sciences, Department of Production and Drug Control, Universidade Federal do Rio Grande do Sul, Brasil
Severino Matias de Alencar, Agri-food Industry, Food and Nutrition Department, Luiz de Queiroz College of Agriculture, University of São Paulo, Brazil
Silvana Nair Leite, Department of Pharmaceutical Sciences, School of Pharmacy, Federal University of Santa Catarina, Brazil
Skylar Carlson, Department of Chemistry, University of the Pacific, USA
Tácio de Mendonça Lima, Faculty of Pharmacy, Department of Pharmaceutical Sciences, Federal Rural University of Rio de Janeiro, Brazil
Taís Gratieri, Faculty of Health Sciences, Pharmacy Department, University of Brasília, Brazil
Vera Marisa Costa, Faculty of Pharmacy, Porto University, Portugal
Technical and Administrative Support
Divisão de Biblioteca e Documentação do Conjunto das Químicas da USP

Editorial Advisory Board
Attilio Converti, University of Genoa, Italy
Franco Maria Lajolo, Universidade of São Paulo, Brazil João Luis Callegari Lopes, Universidade of São Paulo, Brazil
Jorge Mancini Filho, Universidade of São Paulo, Brazil
Maria Helena Gil, Universidade of Coimbra, Portugal
Maria José Soares Mendes Gianini, Universidade of São Paulo, Brazil
Maria Nella Gai, Universidade of Chile, Chile
Mumtaz Iscan, Ankara University, Turkey
Robert Dennis Tanner, Vanderbilt University, USA
Roy Edward Bruns, Universidade of Campinas, Brazil
Rui Curi, Instituto Butantan, Brazil
Suely Vilela, Universidade of São Paulo, Brazil
Victor Manuel Cardoso Figueiredo Balcão, Universidade of Sorocaba, Brazil
SCOPE AND POLICY

The Brazilian Journal of Pharmaceutical Sciences (BJPS) is a peer-reviewed electronic journal published continually by the School of Pharmaceutical Sciences of the University of São Paulo. The purpose of the Brazilian Journal of Pharmaceutical Sciences is to publish manuscripts that significantly contribute to knowledge in all areas of Pharmaceutical Sciences, including:

1. Medicinal Chemistry & Pharmacognosy
2. Pharmaceutical Technology, Drug development, Pharmaceutics & Biopharmaceutics, Drug Delivery
3. Clinical Pharmacy and Pharmacokinetics, Pharmaceutical Care, Pharmaceutical Services
4. Clinical-Bioanalytical Chemistry and Pharmaceutical Analysis
5. Food Science and Nutrition, including Food Analysis and Technology, Nutrigenomics, Immunonutrition, Functional foods and supplements, Food bioactive compounds, the interaction between drugs and foods
6. Vaccines and Biologicals
7. Cosmetology
8. Toxicology

Journal's policy, which are used as guidelines for the review of manuscripts:

1. Out of scope

The paper must report on recent advances in pharmaceutical technology, biopharmaceutics, pharmaceutical biotechnology, medication use, and pharmacist services of major importance.

Immediate rejection criteria:
- a. Description of analytical methods with no relation to pharmaceutics, biopharmaceutics, or pharmaceutical biotechnology.
- b. Mere description of compound synthesis, processes, validation, etc. without any pharmaceutical application.
- c. Inappropriate promotion of a trademark or a product.
- d. Regulatory issues with no relation to pharmaceutics, biopharmaceutics, or pharmaceutical biotechnology.

2. Too preliminary

A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.

Immediate rejection criteria:
- a. No proof of concept in either an in vivo or an in vitro evaluation.
b. No clear indication of the use of the product or formulation.
c. No clear description of the materials & methods used in the pharmaceutical field.
d. Use of inadequate or insufficient methods.
e. Inappropriate statistical analysis.
f. Lack of proper controls.
g. Lack of coherent discussion of the results.

3. **Lack of novelty:**
The study described in the manuscript must represent a novel approach.

*Immediate rejection criteria*

a. Repetition of previously published data, either partially or entirely.
b. Simple variation of parameters of a formulation, processes, synthesis, etc.
c. Modification of well-known delivery systems with no novelty and/or benefit.
d. Plagiarism (intentional and unacknowledged copying of other’s work) and self-plagiarism (re-use of parts of an author’s previously published work without proper attribution).

Before entering the review process, all manuscripts will go through a similarity check using the plagiarism detection software iThenticate. If the editors agree that there is a high percentage of similarity to other texts, the manuscript will be rejected immediately.

The following papers **will not be accepted** for publication:

a. Studies on human subjects not approved by an accredited Ethics Committee or without written informed consent from the subject or legal guardian.
b. Studies on animals not approved by an accredited Ethics and Animal Care Committee.
c. Manuscripts describing plant extract activity that do not identify qualitative and quantitative chemical markers of the extract.

**PREPARATION OF THE MANUSCRIPT**

a. Manuscripts must be submitted in English.
b. Submission of a manuscript to BJPS implies that the data have not been published previously and will not be submitted for publication elsewhere while the manuscript is under review.
c. Co-authors should be individuals who have contributed substantially to the content of the paper.
Manuscripts in accordance to the “Preparing your manuscript section” will be submitted for peer review to at least two independent, anonymous referees indicated by the Associated Editors. Based on peer review, the Associate Editors will suggest manuscript acceptance or not to the Editor-in-Chief, who is responsible for the final decision.

In the case revision is suggested, the authors are asked to resubmit the manuscript incorporating the suggestions and recommendations of the referees within 15 calendar days. If the revised version is not received within the time specified from the date of the notice, the manuscript process will be canceled. All revisions must be accompanied by a letter detailing the changes made to the original document and answering all the reviewer comments, on a point-by-point basis. All alterations must be identified in the revised manuscript.

Manuscripts must have their copyright enclosed as a file to the BJPS. The manuscript will not be sent to reviewers if the signed copyright was not included in the submission package. This document must be hand-signed by all authors, no exception. Later, if the manuscript was accepted, an English certificate will be requested for the last version of the manuscript.

The dates of receipt and acceptance will be published for each article. Authors are expected to return reviewed manuscripts to the Journal within 15 calendar days and to return galley proofs of accepted manuscripts within 72 hours. The total number of “late” days will be added to the submission date at the time of publication.

Authors are required to suggest 4 potential reviewers with information on institutional and e-mail addresses. At least two of these potential reviewers must be from countries other than the corresponding author. The Editors reserve the right to nominate these or other reviewers for manuscript evaluation.

Manuscripts that do not agree to the Instructions will be refused prior to peer review.

**Disclosure instructions**

Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Statement model:**

During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
MANUSCRIPT CATEGORIES

The authors should state in the cover letter that the manuscript is intended to be Full-length Original Paper, Short Communication, Review Article, Mini-review article, Concepts and Comments and Book Reviews.

The Journal will also publish Thematic or Congress Abstracts Supplements under invitation by the Editors or previous approval by the Editorial Board.

BJPS will publish the following type of articles:

Full-length Original Paper
Each manuscript should clearly state its objective or hypothesis; the experimental design and methods used; the essential features of any interventions; the main outcome measures; the main results of the study; and a discussion placing the results in the context of published literature.

The manuscript should contain:
   a. abstract of no more than 200 words
   b. no more than 6 keywords
   c. a running title to be used as a page heading, which should not exceed 60 letters and spaces
   d. manuscript's main body is divided into separate sections (Introduction, Material and Methods, Results and Discussion).
   e. no more than 40 references (without exceptions)
   f. Supplementary data can be submitted as a Supplementary information session.

Short Communication
Short communication is a report on a single subject, which should be concise but definitive. The scope of this section is intended to be wide and encompass methodology and experimental data on subjects of interest to the readers of the Journal.

The manuscript should contain:
   a. abstract of no more than 200 words
   b. no more than 6 keywords
   c. a running title to be used as a page heading, which should not exceed 60 letters and spaces
   d. manuscript's main body is divided into separate sections (Introduction, Material and Methods, Results and Discussion), without a separate section for conclusions
   e. no more than 20 references (without exceptions)
   f. no more than three illustrations (figures and/or tables)
Review Article

A review article should provide a synthetic and critical analysis of a relevant area and should not be merely a chronological description of the literature. A review article by investigators who have made substantial contributions to a specific area of Pharmaceutical Sciences will be published by invitation of the Editors. However, an outline of a review article may be submitted to the Editors without prior consultation. If it is judged appropriate for the Journal, the author(s) will be invited to prepare the article for peer review.

The manuscript should contain:

a. abstract of no more than 250 words
b. no more than 6 keywords
c. a running title to be used as a page heading, which should not exceed 60 letters and spaces
d. manuscript main body divided into sections with appropriate
titles and subtitles
e. no more than 90 references (without exceptions)

Mini-review Article

A mini-review is focused on a restricted part of a subject normally covered in a review article. The structure of the mini-review follows the same rules as the review.

Concepts and Comments

The Concepts and Comments section provides a platform for readers to present ideas, theories and views.

The manuscript should contain:

a. abstract of no more than 250 words
b. no more than 6 keywords
c. a running title to be used as a page heading, which should not exceed 60 letters and spaces
d. manuscript's main body is divided into sections with appropriate
titles and subtitles
e. no more than 40 references (without exceptions)

Book Reviews

Written by experts nominated by the Editors or written by the Authors.

PREPARING YOUR MANUSCRIPT

Cover Letter

It is important that you include a cover letter with your manuscript. Take the time to consider why this manuscript is suitable for publication in the Brazilian Journal of Pharmaceutical Sciences. Why will your paper inspire other members of your field, and how will it drive research forward. Please explain these points in your cover letter.
The cover letter should also contain the following information:

a. Title of article.

b. Name(s), filiation and ORCID number of all author(s).

c. Information of Corresponding Author: name and e-mail (full address and telephone number are optional informations).

**Authorship requirements**

Only people who directly contributed to the intellectual content of the paper should be listed as authors. Manuscripts must be submitted electronically only. Confirmation of submission will be sent by email to all authors, for their agreement.

Authors should meet all of the following criteria, thereby taking public responsibility for the content of the paper:

a. Conceived, planned, and carried out the experiments presented in the manuscript or interpreted the data, or both.

b. Wrote the paper, or reviewed successive versions.

c. Approved the final version.

d. Holding positions of administrative leadership, contributing to patients, and collecting and assembling data, however important to the research, are not by themselves criteria for authorship. Any person who has made a substantial, direct contribution to the work but cannot be considered an author should be cited in the Acknowledgment section, with permission and include a description of his/her specific contribution to the research.

**Text format**

a. The text of a manuscript can only be accepted as a Microsoft Word file created with MS Word as a “doc”, “docx” or “RTF” document.

b. Manuscripts should be sent in 30-36 lines, 1.5 spaced,

c. Each page should contain the page number in the upper right-hand corner starting with the title page as page 1.

d. Report all measurements in Système International, SI (http://physics.nist.gov/cuu/Units) and standard units where applicable

e. Names of plants, animals and chemicals should be mentioned according to International Rules available.

f. Names of drugs can follow the International rules (DCI) or current Brazilian rules (DCB)

g. Trademarks may be mentioned only once in the text (between parenthesis and initial in capital letter)

h. Do not use abbreviations in the title and limit their use in the abstract and text.

i. The length of the manuscript and the number of tables and figures must be kept to a minimum.

j. Ensure that all references are cited in the text.
k. Generic names must be used for all drugs. Instruments may be referred to by proprietary name; the name and country of the manufacturer should be given in parenthesis.

ORGANIZATION OF THE MANUSCRIPT

Most articles published in BJPS will be organized into the following sections:

Title
Running Title Authors (full names)
Corresponding author information (Abbreviated name, institutional address, phone, e-mail, ORCID link)
Abstract, Keywords

INTRODUCTION MATERIAL AND METHODS

First Subtitle (if there is any) Second subtitle (if there is any)

RESULTS

DISCUSSION ACKNOWLEDGMENTS REFERENCES

Tables with a descriptive title and footnote legends
Figures with a descriptive legend and uniformity in format.

Continuous page numbers are required for all pages including figures. There are no specific length restrictions for the overall manuscript or individual sections. However, we request authors to present and discuss their findings concisely. We recognize that some articles will not be best presented in our research article format. If you have a manuscript that would benefit from a different format, please contact the editors for further discussion.

TITLE PAGE

Title
The title should be as short and informative as possible, should not contain non-standard acronyms or abbreviations, and should not exceed two printed lines. The title should be centered and written in bold as the example below:

FREEZE-DRYING OF AMPICILLIN SOLID LIPID NANOPARTICLES USING MANNITOL AS CRYOPROTECTANT

Running title
This short title, to be used as a page heading, should not exceed 60 letters and spaces.

Authors and Affiliations
Full name (matched with superscript numbers identifying affiliation) must be written in bold and centered. Institution(s) (Department, Faculty, University, City, State, Country) of each author (in English must be centered and written in italic.
Example:
Hongmei Xia¹, Yongfeng Cheng², Yinxiang Xu³, Zhiqing Cheng¹

¹College of Pharmacy, Anhui University of Chinese Medicine, Hefei, People’s Republic of China, ²School of Life Science, University of Science and Technology of China, Hefei, People’s Republic of China, ³Zhaoke (Hefei) Pharmaceutical Co. Ltd., Hefei, People’s Republic of China

Corresponding author
One of the authors should be designated as the corresponding author. It is the corresponding author’s responsibility to ensure that the author list is accurate and complete. If the article has been submitted on behalf of a consortium, all consortium members and affiliations should be listed in the Acknowledgments section. Provide the name, email address, and ORCID number of the author to whom correspondence should be sent identified with an asterisk.

Abstract
Since abstracts are published separately by Information Services, they should contain sufficient hard data to be appreciated by the reader. The abstract should not exceed 200 words and should be prepared in a single paragraph without topics and no margins. The abstract should briefly and clearly present the objective, experimental approach, new results as quantitative data if possible, and conclusions. It should mention the techniques used without going into methodological detail and mention the most important results. Abbreviations should be kept to a minimum and should be defined in both the Abstract and text. Please do not include any reference citations in the abstract. If the use of a reference is unavoidable, the full citation should be given within the abstract.

Keywords:
A list of keywords or indexing terms (no more than 6) should be included avoiding generic terms.
Keywords must be separated by dots with only the first letter of the first word in upper case.
Example:
Apoptosis pharmacokinetics. Toxicology.

INTRODUCTION
The Introduction should put the focus of the manuscript into a broader context and reflects the present state-of-art of the subject. This should state briefly and clearly the objectives of the investigation with reference to previous works. The introduction should justify the hypothesis of the study. An extensive review of the literature should be avoided and when possible replaced by recent reviews of the subject.
MATERIAL AND METHODS

These should be described in sufficient detail that the work can be reproduced. Well-established procedures and techniques require only a citation of the original source, except when they are substantially modified. Reports of experimental studies on humans and animals must certify (including the number of protocols) that the research received prior approval by the appropriate institutional review Ethics Committee.

RESULTS

Results must be presented clearly and concisely and in a logical order. This section should provide the results of all of the experiments required to support the conclusions of the paper. When possible, use figures or tables to present data rather than text. Large datasets, including raw data, should be submitted as supplementary files; these are published online and linked to the article.

DISCUSSION

Discussion should interpret the results and assess their significance in relation to existing knowledge. Speculation not warranted by actual data should be avoided. The Discussion should spell out the major conclusions and interpretations of the work including some explanation of the significance of these conclusions.

ACKNOWLEDGMENTS

When appropriate, briefly acknowledge technical assistance, advice, and contributions from colleagues. People who contributed to the work but do not fit the criteria for authors should be listed in the Acknowledgments section, along with their contributions. Donations of animals, cells, or reagents should also be acknowledged. You must also ensure that anyone named in the Acknowledgments agrees to being so named. Financial support for the research and fellowships should be acknowledged in this section (agency and grant number).

Figures

Figures must be submitted in high-resolution version (300 dpi). They must be submitted separately from the text, in the file upload section of the submission platform.

Preparing figure files for submission

The use of figures is mandatory for original articles since it increases the clarity of data. The use of color figures in articles is free of charge. The following guidelines must be observed when preparing figures. Failure to do so is likely to delay the acceptance and publication of the article.

a. Each figure of a manuscript should be submitted as a single file.

b. Figures should be numbered in the order they are first mentioned in the text, and uploaded in this
order.
c. Figure titles and legends should be provided in the main manuscript as a List of Figures, not in the graphic file.
d. The aim of the figure legend should be to describe the key messages of the figure, but the figure should also be discussed in the text.
e. An enlarged version of the figure and its full legend will often be viewed in a separate window online, and it should be possible for a reader to understand the figure without moving back and forth between this window and the relevant parts of the text.
f. The legend itself should be succinct, while still explaining all symbols and abbreviations. Avoid lengthy descriptions of methods. Statistical information should be given as well as the statistical tests used.
g. Arrows or letters should be used in the figure and explained in the legend to identify important structures.
h. Figures with multiple panels should use capital letters A, B, C, etc. to identify the panels.
i. Each figure should be closely cropped to minimize the amount of white space surrounding the illustration. Cropping figures improves accuracy when placing the figure in combination with other elements when the accepted manuscript is prepared for publication.
j. Individual figure files should not exceed 5 MB. If a suitable format is chosen, this file size is adequate for extremely high-quality figures.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures (or tables) that have previously been published elsewhere. In order for all figures to be open-access, authors must have permission from the rights-holder if they wish to include images that have been published elsewhere in non-open-access journals. Permission should be indicated in the figure legend, and the original source included in the reference list.

Supported file type

The following file format can be accepted: TIFF (suitable for images) or JPEG with 300 dpi, and Word file for the manuscript.

Tables

a. Tables must be submitted in Word (.doc) or Excel (.xls), not as an image.
b. Tables must be numbered consecutively with Roman numerals in the text.
c. Tables must have a concise and descriptive title.
d. All explanatory information should be given in a footnote below the table. Footnotes should be used to explain abbreviations and provide statistical information, including statistical tests used.
e. All abbreviations must be defined in this footnote, even if they are explained in the text.
f. Tables must be understandable without referring to the text.
g. Tables occupying more than one printed page should be avoided, if possible.

h. Vertical and diagonal lines should not be used in tables; instead, indentation and vertical or horizontal space should be used to group data.

**Citations**

References should be prepared and listed according to Vancouver's standard reference style. Entries should be arranged in alphabetical order by the author at the end of the paper. All authors’ names should be given. The accuracy and completeness of reference data is the responsibility of the authors.

Only published references should be included in the reference list. Meeting abstracts, conference talks, or papers that have been submitted but not yet accepted should not be cited. Limited citation of unpublished work should be included in the body of the text only. All personal communications should be supported by a letter from the relevant authors.

References should be cited in the text by the authors’ names, with only the first letter in capital letter followed by the year of publication. For more than three authors, the first has to be cited followed by the expression *et al.* (in italic). Small letters close to the year must differentiate references of the same authors and year of publication.

**Examples:**

(Zhang, 2017)

(Ima, Souza, 2015)

(Fujisawa, Atsumi, Kadoma, 1989)(Aviral *et al.*, 2009)

(Liu *et al.*, 2011a)(Liu *et al.*, 2011b)

**References**

**Published Papers:** Write all author’s names up to 6 authors and followed by *et al.* (in case there are more than 6), Title (Only the first letter in upper case). Journal abbreviation without dots. Year;Volume(issue number):first page-last page.


**Article accepted for publication but not yet published**: First 6 authors followed by et al. Title. Journal (abbreviation in normal font), Year of expected publication (in press) at the end of the citation.


**Internet Communication**: Ensure that URLs are active and available. Provide DOI, if available.


**Whole Book**: Authors, Book title, Edition, City, Publisher, Year.


**Laws**


**Book Chapter**: Authors, Chapter Title, Editors, Book title, Edition, City, Publisher, Year, Pages of citation.

**Conference or Symposium Proceedings**: Cite papers only from published proceedings.


**Report**


**Audiovisual Material**


**Computer Program**


**Patent**


**Thesis and Dissertations**

Joselevitch C. Visão no ultravioleta em Carassius auratus (Ostariophysi, Cypriformes, Cyprinidae):


**Unpublished results and Personal communication:** Reference should appear in the text with the individual name(s) and initials and not in the reference list.

(Santos CS, da-Silva GB, Martins LT, unpublished results).

It is assumed that the author has obtained permission from the source when personal communication is cited.

**HOW TO SUBMIT THE MANUSCRIPT**

Submission should be sent electronically through the ScholarOne system (https://mc04.manuscriptcentral.com/bjps-scielo).

If you need further assistance, please contact the Journal staff (bjps@usp.br).